Irv Weissman (Norbert von der Groeben for Stanford)
March 12, 2020 06:55 AM EDTUpdated 08:39 AM
People
Deals

Stan­ford stem cell pi­o­neer nets $194M from Gilead-Forty Sev­en buy­out

Jason Mast

Editor

Gilead’s $4.9 bil­lion buy­out of Forty Sev­en, their largest in three years, brought with it a sub­stan­tial wind­fall for the biotech’s founder, CEO and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times